IPF Italian observational study (FIBRONET)

Study identification

• EU PAS number:
  EUPAS14067
• Study ID:
  14068
• Official title and acronym:
  IPF Italian observational study (FIBRONET)
• DARWIN EU® study:
  No
• Study countries:
  Italy
• Study description:
  Long-term data on the natural course of IPF in Italy are scarce. Further, there is limited information on IPF in terms of patient characteristics and disease management. The purpose of the present study is to evaluate the characteristics, management and clinical course of patients with IPF as treated under real-world in Italian Pulmonary Centres, in terms of symptoms, lung function and exercise tolerance during 12 months of observation. In particular, the study aims to provide information on disease characteristics and treatment modalities (at enrolment) and on disease progression, HRQoL and health care sector-related costs according to the Italian National Health Service (INHS) point of view (during 12 months of observation).
• Study status:
  Finalised

Research institutions and networks

Institutions

Boehringer Ingelheim

Study timelines

Date when funding contract was signed

Planned:26/06/2015

Actual:26/06/2015

Study start date

Planned:17/11/2015

Actual:17/11/2015

Date of final study report

Planned:31/10/2018

Actual:10/04/2019

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Boehringer Ingelheim Italia S.p.A.

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable

Other study registration identification numbers and links

1199.262
NCT02803580